AIM: To assess whether response to medications for alcohol use disorders varies by genotype. METHODS: Systematic review and meta-analysis. RESULTS: We found no studies that assessed the clinical utility of genotype-guided dosing strategies or genotype-guided medication selection, and none randomized by genotype. All included studies assessed the association between genotype and response to medication. Of 15 included studies, eight (n = 1365 participants) assessed variation in naltrexone response and polymorphisms of OPRM1. Our meta-analyses for return to heavy drinking found no significant difference between A allele homozygotes and those with at least one G allele, both without (risk difference: 0.26; 95% CI: -0.01-0.53; n = 174) and with inclusion of studies rated as high or unclear risk of bias (risk difference: 0.14; 95% CI: -0.03-0.3; n = 382). For all other polymorphism-medication pairs, we found just one eligible study. CONCLUSION: Estimates of effect for return to heavy drinking suggest it is possible that patients with at least one G allele of A118G polymorphism of OPRM1 might be more likely to respond to naltrexone, but confidence intervals were wide; additional studies are needed to improve confidence in the estimates.
AIM: To assess whether response to medications for alcohol use disorders varies by genotype. METHODS: Systematic review and meta-analysis. RESULTS: We found no studies that assessed the clinical utility of genotype-guided dosing strategies or genotype-guided medication selection, and none randomized by genotype. All included studies assessed the association between genotype and response to medication. Of 15 included studies, eight (n = 1365 participants) assessed variation in naltrexone response and polymorphisms of OPRM1. Our meta-analyses for return to heavy drinking found no significant difference between A allele homozygotes and those with at least one G allele, both without (risk difference: 0.26; 95% CI: -0.01-0.53; n = 174) and with inclusion of studies rated as high or unclear risk of bias (risk difference: 0.14; 95% CI: -0.03-0.3; n = 382). For all other polymorphism-medication pairs, we found just one eligible study. CONCLUSION: Estimates of effect for return to heavy drinking suggest it is possible that patients with at least one G allele of A118G polymorphism of OPRM1 might be more likely to respond to naltrexone, but confidence intervals were wide; additional studies are needed to improve confidence in the estimates.
Authors: R L Bell; S Hauser; Z A Rodd; T Liang; Y Sari; J McClintick; S Rahman; E A Engleman Journal: Int Rev Neurobiol Date: 2016-03-21 Impact factor: 3.230
Authors: Aaron C Lim; Erica N Grodin; Rejoyce Green; Alexandra Venegas; Lindsay R Meredith; Kelly E Courtney; Nathasha R Moallem; Philip Sayegh; Edythe D London; Lara A Ray Journal: Am J Drug Alcohol Abuse Date: 2020-04-28 Impact factor: 3.829
Authors: Scott H Stewart; Kimberly S Walitzer; Javier Blanco; Denise Swiatek; Linda Paine Hughes; Adolfo Quiñones-Lombraña; Kathleen Shyhalla Journal: J Subst Abuse Treat Date: 2019-05-04
Authors: Emily E Hartwell; Richard Feinn; Paige E Morris; Joel Gelernter; John Krystal; Albert J Arias; Michaela Hoffman; Ismene Petrakis; Ralitza Gueorguieva; Joseph P Schacht; David Oslin; Raymond F Anton; Henry R Kranzler Journal: Addiction Date: 2020-02-11 Impact factor: 6.526
Authors: Aaron C Lim; Dara G Ghahremani; Erica N Grodin; ReJoyce Green; Spencer Bujarski; Emily E Hartwell; Kelly E Courtney; Kent Hutchison; Karen Miotto; Lara A Ray Journal: Drug Alcohol Depend Date: 2019-05-09 Impact factor: 4.852
Authors: Daniel J O Roche; Constantine J Trela; Maria Argos; Farzana Jasmine; Muhammad G Kibriya; Habibul Ahsan; Andrea C King Journal: Alcohol Alcohol Date: 2019-01-09 Impact factor: 3.913
Authors: Lara A Ray; ReJoyce Green; Daniel J O Roche; Spencer Bujarski; Emily E Hartwell; Aaron C Lim; Taylor Rohrbaugh; Dara Ghahremani; Kent Hutchison; Karen Miotto Journal: Alcohol Clin Exp Res Date: 2018-02-01 Impact factor: 3.928